Dr. Siegel is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
92 2nd St
Hackensack, NJ 07601Phone+1 551-996-8704Fax+1 551-996-0582
Summary
- Dr. David Siegel is an oncologist in Hackensack, NJ and is affiliated with multiple hospitals in the area, including Hackensack Meridian Health Hackensack University Medical Center and MedStar Georgetown University Hospital. He received his medical degree from NYU School of Medicine and has been in practice 31 years. He specializes in hematologic oncology and is experienced in multiple myeloma, bone marrow transplant, AL amyloidosis and Waldenstroms Macroglobulinemia.
Education & Training
- Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 1989 - 1992
- NYU Grossman School of MedicineResidency, Internal Medicine, 1987 - 1989
- NYU Grossman School of MedicineInternship, Internal Medicine, 1986 - 1987
- New York University School of MedicineClass of 1986
- New York UniversityPhD, 1985
- New York UniversityMSc, 1984
- American Association of ImmunologistsCertificate, Advanced Immunology Course, 1984
- Cook College, Rutgers UniversityB.S., With Honors, 1979
Certifications & Licensure
- AZ State Medical License 2024 - 2027
- NH State Medical License 2024 - 2026
- NY State Medical License 1987 - 2026
- OH State Medical License 2024 - 2026
- VT State Medical License 2024 - 2026
- CO State Medical License 2024 - 2025
- CT State Medical License 2024 - 2025
- American Board of Internal Medicine Internal Medicine
- Join now to see all
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013
- Fellow (FACP) American College of Physicians, 2002
- Young Investigator Award ASCO, 1991
- Join now to see all
Clinical Trials
- Safety Study of IPI-504 in Patients With Relapsed and Relapsed Refractory Multiple Myeloma Start of enrollment: 2005 Jun 01
- High-Dose Interferon Alfa in Treating Patients With Stage II or StageIII Melanoma Start of enrollment: 2000 Jan 01
- Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney Dysfunction Start of enrollment: 2009 Jan 21
- Join now to see all
Publications & Presentations
PubMed
- Pomalidomide/Daratumumab/Dexamethasone in Relapsed or Refractory Multiple Myeloma: Final Overall Survival From MM-014.Nizar J Bahlis, Christy Samaras, Donna Reece, Michael Sebag, Jeffrey Matous
Clinical Lymphoma, Myeloma & Leukemia. 2024-12-01 - Post-ASCT consolidation with elotuzumab, lenalidomide, and dexamethasone or elotuzumab, pomalidomide, and dexamethasone in high-risk and ultra-high-risk multiple myelo...Eli Zolotov, Maciej Kabat, Harsh Parmar, Palka Anand, Joshua Zenreich
Leukemia & Lymphoma. 2024-12-01 - Intra-marrow delivery of human interleukin-6-loaded biodegradable microspheres promotes growth of patient-derived multiple myeloma cells in mice.Manpreet Bariana, Weiwei Wang, Zhuozhuo Yin, Jingyu Sun, Shabnam Samimi
Haematologica. 2024-09-12
Journal Articles
- Carfilzomib vs Bortezomib in Patients with Multiple Myeloma and Renal Failure: A Subgroup Analysis of ENDEAVORRuben Niesvizky, David Siegel, Ralph Boccia, Blood
- Updated survival analyses after prolonged follow-up of the phase 2, multicenter CReST study of bortezomib in relapsed or refractory multiple myelomaJagannath S, Barlogie B, Berenson JR, Siegel DS, Irwin D, Richardson PG,Niesvizky R, Alexanian R, Limentani SA, Alsina M, esseltine DL, Anderson KC, Br J Haematol, 1/1/2014
- Phase I Trial of Anti-CS1 Monoclonal Antibody elotuzumab in Combination With Bortezomib in the Treatment of Relapsed/Refractory Multiple MyelomaJakubowiak AJ, Benson DM, Bensinger W, Siegel DS, Zimmerman TM, Mohrbacher A, Richardson PG, Afar De, Singhal AK, Anderson KC, J Clin Oncol, 1/30/2012
- Join now to see all
Books/Book Chapters
Lectures
- CAR T-Cell Therapy in Lymphoma, Myeloma, and Leukemia _ Clinical Updates and Innovations61st Annual American Society of Hematology Meeting - Orlando, FL - 12/7/2019
- Efficacy and Safety of Carfilzomib and Dexamethasone in Lenalidomide Exposed and Refractory Multiple Myeloma Patients: Combined Analysis of Carfilzomib Trials2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Safety and Efficacy Data for Combined Checkpoint Inhibition with Ipilimumab (Ipi) and Nivolumab (Nivo) As Consolidation Following Autologous Stem Cell Transplantation ...2018 ASH Annual Meeting - San Diego, CA - 12/1/2018
- Join now to see all
Press Mentions
- Immunogenomics Is on the Way UpAugust 12th, 2024
- First Patient Dosed with Off-the-Shelf UCARTCS1 Product Candidate for Relapsed/Refractory Multiple MyelomaNovember 20th, 2019
- FDA Approves Kyprolis (Carfilzomib) Once-Weekly Kd70 Regimen for Relapsed or Refractory Multiple MyelomaNovember 29th, 2011
- Join now to see all
Committees
- Working Group Member, International Waldenstrom's Macroglobulenemia Working Group 2011 - 2016
- Steering Committee, MMRF 2005 - 2016
- group Member, International Myeloma Working Group 2005 - 2016
Research History
- Chief, Myeloma Division12 current clinical trials2002 - 2016
Professional Memberships
- Member
- Fellow
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: